← Back to Clinical Trials
Recruiting NCT07451600

NCT07451600 Effectiveness of TMS on Spasticity and Balance for Patients With MS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07451600
Status Recruiting
Phase
Sponsor Ankara Etlik City Hospital
Condition Multiple Sclerosis
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2026-03-01
Primary Completion 2026-10-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
rTMSsham rTMS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2026-03-01 with a primary completion date of 2026-10-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Recently, non-invasive brain stimulation modalities such as transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation have become treatment options. Among these methods, rTMS is a non-invasive brain stimulation technique that can affect descending corticospinal pathways, thereby modulating cortical excitability in the motor area where it is applied. This study will examine the effect of rTMS application on spasticity and balance in patients with multiple sclerosis. In addition, the indirect effects of the applications on gait pattern, joint range of motion, and pain will be evaluated.

Eligibility Criteria

Inclusion Criteria: * Being between the ages of 18 and 60 * Having been diagnosed with multiple sclerosis for more than six months * Having spasticity levels between 1 and 3 on the Modified Ashworth Scale (MAS) in the evaluated extremity * Having an EDSS SCORE between 0 and 6.5 * Voluntarily participating in the study Exclusion Criteria: * Poor general health (heart failure, COPD, etc.) * Presence of wound lesions on the skin * Presence of metal implants in the body * Pregnancy * Presence of a severe infection * Diagnosis of malignancy * Presence of a bleeding disorder * Use of a pacemaker * Presence of cardiac rhythm disorder * Presence of neurological disease other than multiple sclerosis * History of epilepsy * History of alcohol use * Change in medication within the last 6 months * Refusal to participate in the study

Contact & Investigator

Central Contact

Melike Çil, specialist

✉ melike9671@gmail.com

📞 +90 0312 797 00 00

Principal Investigator

Özgür Zeliha Karaahmet, professor

STUDY DIRECTOR

Ankara Etlik City Hospital

Frequently Asked Questions

Who can join the NCT07451600 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07451600 currently recruiting?

Yes, NCT07451600 is actively recruiting participants. Contact the research team at melike9671@gmail.com for enrollment information.

Where is the NCT07451600 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT07451600 clinical trial?

NCT07451600 is sponsored by Ankara Etlik City Hospital. The principal investigator is Özgür Zeliha Karaahmet, professor at Ankara Etlik City Hospital. The trial plans to enroll 24 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology